Clinical response to ketoconazole of HIV-related oral candidosis is predicted by Odds' relative growth method of susceptibility testing.
In-vitro ketoconazole susceptibility was assessed by measuring an isolate's relative growth in medium containing a fixed concentration of ketoconazole as a percentage of growth in drug-free medium. One hundred specimens from HIV-positive patients with candidosis were tested. Each patient's response was assessed following one week's treatment with ketoconazole 400 mg/day. A relative growth in ketoconazole of >75% predicted clinical failure of ketoconazole with a specificity of 97% and sensitivity of 79%.
Cartledge
J D
JD
Department of HIV & Genito-Urinary Medicine, St Stephen's Centre, Chelsea & Westminster Healthcare NHS Trust, London, UK.
Midgley
J
J
Gazzard
B G
BG
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000935:Antifungal Agents / Q000494:pharmacology / Q000627:therapeutic use; D002175:Candida / Q000187:drug effects; D002180:Candidiasis, Oral / Q000188:drug therapy*; D015725:Fluconazole / Q000494:pharmacology; D006801:Humans; D007654:Ketoconazole / Q000494:pharmacology* / Q000627:therapeutic use*; D008826:Microbial Sensitivity Tests / Q000379:methods*; D011237:Predictive Value of Tests
D000935:Antifungal Agents; D015725:Fluconazole; D007654:Ketoconazole